Full Press Release Details
Amends Shareholder Rights Plan
BEIJING, China, February 22, 2023 /Business Wire/
-- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products
in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date
of the plan from February 22, 2023 to February 22, 2024.
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical
company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines
against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal
disease, mumps, etc.
The COVID-19 vaccine, CoronaVac , has been approved
for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive , passed WHO prequalification requirements
in 2017. The EV71 vaccine, Inlive , is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized
in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the
SINOVAC was the first company to be granted approval
for its H1N1 influenza vaccine Panflu.1 , which has supplied the Chinese government's vaccination campaign and stockpiling program.
The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu , to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine
R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to
conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please visit the Company's
website at www.sinovac.com.
Safe Harbor Statement
This press release may include certain statements that are not descriptions
of historical facts, but are forward-looking statements. These statements are made under the "safe harbor" provisions of the
U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will,"
"expects," "anticipates," "future," "intends," "plans," "believes,"
"estimates" and similar statements. Forward-looking statements involve risks, uncertainties and other factors that could cause
actual results to differ materially from those contained in any such statements. In particular, the outcome of any litigation is uncertain,
and the Company cannot predict the potential results of the litigation it filed or filed against it by others. Additionally, the triggering
of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price as a
result of the trigger of the rights plan.
Sinovac Biotech Ltd.
Tel: +86-10-8279-9871 or
Fax: +86-10-6296-6910
Email: ir@sinovac.com
U.S.: 1-646-308-1707
Email: william.zima@icrinc.com